HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Discovery of novel GPVI receptor antagonists by structure-based repurposing.

Abstract
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thienopyridines and aspirin. Although effective, these drugs carry risks of increased bleeding and drug 'resistance', underpinning a drive for new antiplatelet agents. To discover such drugs, one strategy is to identify a suitable druggable target and then find small molecules that modulate it. A good and unexploited target is the platelet collagen receptor, GPVI, which promotes thrombus formation. To identify inhibitors of GPVI that are safe and bioavailable, we docked a FDA-approved drug library into the GPVI collagen-binding site in silico. We now report that losartan and cinanserin inhibit GPVI-mediated platelet activation in a selective, competitive and dose-dependent manner. This mechanism of action likely underpins the cardioprotective effects of losartan that could not be ascribed to its antihypertensive effects. We have, therefore, identified small molecule inhibitors of GPVI-mediated platelet activation, and also demonstrated the utility of structure-based repurposing.
AuthorsLewis Taylor, Sridhar R Vasudevan, Chris I Jones, Jonathan M Gibbins, Grant C Churchill, R Duncan Campbell, Carmen H Coxon
JournalPloS one (PLoS One) Vol. 9 Issue 6 Pg. e101209 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID24971515 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cardiotonic Agents
  • Platelet Membrane Glycoproteins
  • Small Molecule Libraries
  • platelet membrane glycoprotein VI
  • Losartan
  • Cinanserin
Topics
  • Amino Acid Sequence
  • Cardiotonic Agents (chemistry, pharmacology)
  • Cinanserin (chemistry, pharmacology)
  • Humans
  • Losartan (chemistry, pharmacology)
  • Molecular Docking Simulation
  • Molecular Sequence Data
  • Platelet Activation
  • Platelet Membrane Glycoproteins (antagonists & inhibitors, chemistry, metabolism)
  • Protein Binding
  • Small Molecule Libraries (chemistry, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: